First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
First Presentation Of Year 4 BIMZELX® (Bimekizumab-Bkzx) Data Showed Long-Term Maintenance Of Complete Skin Clearance In Moderate-To-Severe Plaque Pso menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology, discusses unique challenges dermatologists face when treating patients with skin of color, who may present differently from White patients.
Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, announced a large-scale, randomized-controlled trial dedicated to patients across all skin tones with moderate to severe plaque psoriasis.